Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18 - CISMeF
Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18NCIt concept
Preferred Label : Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18;
NCIt synonyms : Anti-VEGF/TGF-beta Bifunctional Antibody Fusion Protein ZGGS18; Anti-VEGF/Anti-TGF-beta Bispecific Antibody Fusion Protein ZGGS18; VEGF x TGF-beta Bispecific Antibody Fusion Protein ZGGS18;
NCIt definition : A bifunctional antibody fusion protein targeting both vascular endothelial growth
factor (VEGF) and the pro-inflammatory cytokine human transforming growth factor beta
(TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-VEGF/TGF-beta
bispecific antibody fusion protein ZGGS18 targets, binds to and neutralizes both VEGF
and TGF-beta. This prevents VEGF- and TGF-beta-mediated signaling and abrogates VEGF/VEGFR-induced
angiogenesis and TGF-beta-mediated induction of VEGF, which further inhibits angiogenesis.
It also inhibits TGF-beta-mediated immunosuppression, thereby enhancing anti-tumor
immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells leading to tumor cell death. VEGF
is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.
TGF-beta, dysregulated in many types of cancer, plays a key role in immunosuppression
in the TME, enhances tumor cell proliferation, and promotes cancer progression.;